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β-amyloid deposition is shifted to the vasculature
and memory impairment is exacerbated when
hyperhomocysteinemia is induced in APP/PS1
transgenic mice
Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun and Donna M Wilcock*

Abstract
Introduction: Vascular dementia is the second most common cause of dementia after Alzheimer’s disease (AD). In
addition, it is estimated that almost half of all AD patients have significant cerebrovascular disease comorbid with
their AD pathology. We hypothesized that cerebrovascular disease significantly impacts AD pathological
progression.
Methods: We used a dietary model of cerebrovascular disease that relies on the induction of
hyperhomocysteinemia (HHcy). HHcy is a significant clinical risk factor for stroke, cardiovascular disease and type 2
diabetes. In the present study, we induced HHcy in APP/PS1 transgenic mice.
Results: While total β-amyloid (Aβ) load is unchanged across groups, Congophilic amyloid deposition was
decreased in the parenchyma and significantly increased in the vasculature as cerebral amyloid angiopathy
(CAA; vascular amyloid deposition) in HHcy APP/PS1 mice. We also found that HHcy induced more microhemorrhages in
the APP/PS1 mice than in the wild-type mice and that it switched the neuroinflammatory phenotype from an M2a
biased state to an M1 biased state. Associated with these changes was an induction of the matrix metalloproteinase
protein 2 (MMP2) and MMP9 systems. Interestingly, after 6 months of HHcy, the APP/PS1 mice were cognitively
worse than wild-type HHcy mice or APP/PS1 mice, indicative of an additive effect of the cerebrovascular pathology
and amyloid deposition.
Conclusions: These data show that cerebrovascular disease can significantly impact Aβ distribution in the brain,
favoring vascular deposition. We predict that the presence of cerebrovascular disease with AD will have a significant
impact on AD progression and the efficacy of therapeutics.

Introduction
Vascular dementia (VaD) is a term that encompasses
many different causes of vascular disease and dysfunction
in the brain that can lead to cognitive impairment [1]. Included in this assortment are stroke, aneurysm, damage
due to chronic hypoperfusion and damage due to chronic
hypertension. VaD is the second most common cause of
dementia behind Alzheimer’s disease (AD). Furthermore,
it is estimated that approximately 40% of AD patients also
have cerebrovascular disease as a comorbidity [2-4]. It
* Correspondence: donna.wilcock@uky.edu
Department of Physiology, Sanders-Brown Center on Aging, University of
Kentucky, 800 S. Limestone St., Lexington, KY 40536, USA

is likely that the presence of cerebrovascular disease independently contributes to the clinical symptoms of
dementia.
We recently showed that induction of hyperhomocysteinemia in wild-type (WT) mice results in cognitive deficits,
neuroinflammation and cortical microhemorrhages [5].
Homocysteine is a non-protein-forming sulfur amino acid
involved in methylation and transsulfuration [6]. It is the
product of the methylation cycle and also a substrate for
cysteine biosynthesis. Elevated levels of homocysteine,
termed hyperhomocysteinemia (HHcy), is considered a
risk factor for cardiovascular and cerebrovascular diseases
[7]. HHcy itself is sufficient to induce cognitive deficits in
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both rat and mouse models [8,9]. In mice, HHcy is induced by administering a diet deficient in vitamins B6 and
B12 as well as folate, and supplemented with methionine.
This diet then drives the metabolic pathway to produce
HHcy with minimal breakdown into cysteine.
In the present study, we hypothesized that cerebrovascular disease would significantly alter AD pathological
progression. To test this possibility, we administered a
diet to induce HHcy in APP/PS1 transgenic mice. We
administered the diet for 6 months, beginning when the
mice were 6 months of age. Researchers in previously
published studies using models of HHcy in APP transgenic mice have focused on total Aβ changes and have
reported both no change in Aβ [10,11] and also modest
increases in Aβ [12,13]. Interestingly, the investigators in
these studies did not examine cerebrovascular changes
or neuroinflammation. In our present study, we found
that amyloid-β (Aβ) levels were not affected by HHcy,
but we observed that the deposited amyloid was now
more associated with the vasculature. We noted an altered neuroinflammatory response and an additive effect
of HHcy on spatial memory impairment in APP/PS1
mice.

Materials and methods
Animals

Forty APP/PS1 mice [14], age 6 months, were placed on
either a diet with low levels of folate, vitamins B6 and
B12 and enriched with methionine (HHcy study group;
n = 20, comprising 12 females and 8 males) or a control
diet that nutritionally matched the experimental diet
with normal levels of methionine, folate and vitamins B6
and B12 (control group; n = 20, comprising 12 females
and 8 males). Additionally, 32 WT mice (C57BL/6 littermate controls from the breeding of the APP/PS1
mice), age 6 months, were placed on either the HHcy
diet (n = 16, comprising 8 females and 8 males) or the
control diet (n = 16, comprising 8 females and 8 males).
The HHcy diet was Harlan Teklad TD97345, and the
control diet was Harlan Teklad 5001 C (both from Harlan
Laboratories, Madison, WI, USA). All mice received the
diet for 6 months. Mice were weighed weekly to ensure
that no significant malnourishment due to the diet was
occurring. The study was approved by the University of
Kentucky Institutional Animal Care and Use Committee
and conformed to the National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals. For all
analyses, sex differences were analyzed and none were
noted, so males and females were combined.
Behavior testing

Radial arm water maze testing was performed at the
University of Kentucky Rodent Behavior Core. The 2day radial arm water maze protocol was carried out as
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previously published [15]. Briefly, a six-arm maze was
submerged in a pool of water, and a platform was placed
at the end of one arm (equipment and tracking software
from Noldus Information Technology, Leesburg VA,
USA). Each mouse was subjected to 15 trials per day for
2 days. Each mouse began each trial in a different arm
while the arm containing the platform remained the
same. The number of errors (incorrect arm entries) was
counted over a 1-minute period. The errors were averaged over three trials, resulting in ten blocks for the 2day period: Day 1 comprised blocks 1 to 5, and day 2
comprised blocks 6 to 10.
Tissue processing and histology

After the mice were injected with a lethal dose of pentobarbital, we collected their blood for plasma, and the
mice were perfused intracardially with 25 ml of normal
saline. The brains were rapidly removed and bisected in
the midsagittal plane. The left half was immersion-fixed
in 4% paraformaldehyde for 24 hours, and the right half
was dissected into anterior cerebral cortex, posterior
cerebral cortex, striatum, hippocampus, thalamus, cerebellum and rest of brain. The posterior cerebral cortex
and rest of brain were combined and immediately homogenized in phosphate-buffered saline (PBS) for zymography (see detailed methodology below). The remaining
pieces were flash-frozen in liquid nitrogen and stored at
−80°C. The left hemibrain was passed through a series
of 10%, 20% and 30% sucrose solutions for cryoprotection, and then 25-μm frozen horizontal sections were
collected serially with a sliding microtome and afterward
stored floating in PBS containing sodium azide at 4°C.
Plasma was analyzed by a veterinary reference diagnostics service for lipid and homocysteine levels (ANTECH
Diagnostics, Fishers, IN, USA).
Eight sections equally spaced 600 μ apart were selected
for free-floating immunohistochemistry for total Aβ
(1:3,000 dilution rabbit polyclonal antibody; Invitrogen,
Carlsbad, CA, USA) and CD45 (1:3,000 dilution rat
monoclonal antibody; Thermo Scientific, Rockford, IL,
USA). The method used for free-floating immunohistochemistry has been described previously [16]. Sixteen
sections equally spaced 300 μ apart were mounted on
slides and stained for Prussian blue as described previously [17].
Enzyme-linked immunosorbent assay measurement

Protein was extracted for Aβ analysis from the right
frontal cortex using a two-step extraction method. First,
the brain was homogenized in PBS containing a complete
protease and phosphatase inhibitor (Pierce Biotechnology,
Rockford, IL, USA). These samples were centrifuged at
16,000 × g at 4°C for 1 hour. The supernatant was removed and became the “soluble” extract. The resulting
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pellet was homogenized in 100 μl of 70% formic acid and
centrifuged again at 16,000 × g at 4°C for 1 hour. The
supernatant was removed and neutralized 1:20 with 1 M
Tris-HCl and became the “insoluble” extract. The protein
concentration for both the soluble and insoluble extracts
was determined using a bicinchoninic acid (BCA) protein
assay according to the manufacturer’s instructions (Thermo
Scientific). We used the Meso Scale Discovery multiplex
enzyme-linked immunosorbent assay (ELISA) system to
measure Aβ38, Aβ40 and Aβ42 (Meso Scale Discovery,
Rockville, MD, USA). The ELISA experiments were run according to the kit manufacturer’s instructions.

Technologies, Grand Island, NY, USA) according to the
manufacturer’s instructions. RNA was quantified using a
NanoDrop spectrophotometer (Thermo Scientific), and
cDNA was produced using a High Capacity cDNA kit
(Life Technologies) according to the manufacturer’s instructions. Real-time RT-PCR was performed using a TaqMan gene expression assay kit (Life Technologies)
according to the manufacturer’s instructions and as previously described [18]. All genes were normalized to 18S
ribosomal RNA. We determined fold changes using the δ
method for mice that were fed the experimental diet compared to mice given the control diet [19].

Quantitative real-time RT-PCR

Gelatin zymography

RNA was extracted from the frozen right hippocampus using the TRIzol Plus RNA Purification Kit (Life

The enzymatic activities of tissue matrix metalloproteinases were measured by performing gelatin zymography in

Figure 1 Cognitive deficits are additive when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. (A) Two-day radial arm
water maze data are graphed. The mean number of errors per trial were calculated for blocks 1 to 10 (each block comprised three trials). Asterisks
indicate significant differences for hyperhomocysteinemia (HHcy) wild-type (WT) mice (n = 16), APP/PS1 control mice (n = 20) and HHcy APP/PS1
mice (n = 20) compared to WT control mice (n = 16). **P < 0.01. (B) Final block data only are graphed (block 10). Asterisks indicate significance
compared to WT controls. **P < 0.01.
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brain samples. Protein was extracted from fresh brain tissue in PBS, specifically the right posterior cerebral cortex
and midbrain together, and quantified immediately using
a BCA protein assay kit (Pierce Biotechnology) according
to the manufacturer’s instructions. Protein samples were
immediately separated on a precast 10% gelatin zymogram
gel (Life Technologies). The gel was removed, incubated
in zymogram renaturing buffer for 30 minutes, equilibrated for 30 minutes in zymogram developing buffer at
room temperature and then incubated overnight at 37°C
with gentle agitation in fresh zymogram developing buffer
(all buffers obtained from Life Technologies). The next
day, the gel was washed gently with water and incubated
in IRDye blue protein stain, a Coomassie blue stain (LICOR Biosciences, Lincoln, NE, USA). The gel was stained
for 1 hour and then destained in H2O until clear band
resolution was apparent (approximately 1 hour). The gel
was scanned on an Odyssey imager, and semiquantitative
densitometric analysis was performed using Odyssey imaging software (LI-COR Biosciences).
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Analysis

Data are presented as mean ± SEM. Statistical analysis
was performed using the JMP statistical analysis software
program (SAS Institute, Cary, NC, USA). Radial arm
water maze data and rotarod performance were analyzed
by repeated-measures analysis of variance (ANOVA) to
assess the overall effect of diet. For the radial arm water
maze data, we also performed Student’s t-test on individual block data. For gene expression analysis, we used the
Mann–Whitney–Wilcoxon test. For other data, one-way
ANOVA and Student’s t-test were performed. Statistical
significance was assigned when the P-value was <0.05.

Results
Administration of the diet deficient in B6, folate and B12
and enriched in methionine for 6 months, from 6 to
12 months of age, resulted in significant elevations in
plasma homocysteine levels in both WT and APP/PS1
transgenic mice (WT control: 6.85 ± 0.8 μmol/L, WT HHcy:
68.23 ± 12.1 μmol/L, APP/PS1 control: 7.65 ± 1.4 μmol/L

Figure 2 Total β-amyloid is unaltered by hyperhomocysteinemia in APP/PS1 transgenic mice. Total β-amyloid (Aβ) immunohistochemistry
in the hippocampus of APP/PS1 mice on either the control diet (A) or the hyperhomocysteinemia (HHcy) diet (B). (A) shows the CA1, CA3 and
dentate gyrus (DG) for orientation. Original magnification = 40×. Scale = 120 μm. (C) Quantification of percent area occupied by positive staining
for Aβ in the hippocampus (HPC) and frontal cortex (FCX) of APP/PS1 transgenic mice fed either the control diet (n = 20, black bars) or the HHcy
diet (n = 20, white bars). Error bars show SEM. (D) Biochemical quantification of Aβ1–38, Aβ1–40 and Aβ1–42 in both the soluble and insoluble
protein extracts ± SEM.
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and APP/PS1 HHcy: 64.21 ± 8.3 μmol/L). There was no
significant difference between WT and APP/PS1 transgenic
mice in the plasma homocysteine levels induced by the diet.
In C57BL/6 mice, normal homocysteine levels are considered to be 5 to 12 μmol/L. Hyperhomocysteinemia can
be categorized as mild (12 to 30 μmol/L), moderate (30 to
100 μmol/L) or severe (>100 μmol/L) [20]. On the basis of
the levels we observed in our experimental mice, HHcy
levels were moderate. None of our mice reached the plasma
level of homocysteine classified as severe HHcy.
In the 2-day radial arm water maze task, WT mice
began the test naïve and made an average of five errors
per trail (Figure 1). The WT control mice were making
less than one error per trail by the end of the first day,
and this performance continued into day 2. HHcy WT
mice were impaired in performing the task and were significantly impaired compared to WT control mice throughout the second day of testing (P < 0.01) (Figure 1A). APP/
PS1 transgenic mice fed the control diet showed a level of
impairment similar to that observed in the HHcy WT mice
(P < 0.01) (Figure 1A). Interestingly, HHcy APP/PS1 transgenic mice showed more severe impairment, with an apparent additive effect of HHcy combined with the APP/PS1
transgene (P < 0.01) (Figure 1A). When we plotted the
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mean number of errors per trial for the final block of day 2,
we found that both the HHcy WT mice and the APP/PS1
mice were making a mean of approximately 1.8 errors per
trial, whereas the HHcy APP/PS1 mice were making a
mean of around 4.0 errors per trial (P < 0.01) (Figure 1B).
To determine whether HHcy had resulted in Aβ changes
in the APP/PS1 mice, we first assessed total Aβ by immunohistochemistry. The control APP/PS1 transgenic mice
showed a typical staining pattern for the 12-month age
point in both the hippocampus (Figure 2A) and the frontal
cortex. However, no change in total Aβ staining was observed in HHcy APP/PS1 mice (Figure 2B). Quantitatively,
total Aβ staining was unchanged with HHcy in APP/PS1
mice in either the frontal cortex or the hippocampus (Figure 2C). To confirm that no changes in Aβ production
were occurring, we performed biochemical analysis of brain
tissue using an Aβ triplex ELISA kit that measures Aβ1–38,
Aβ1–40 and Aβ1–42 (Meso Scale Discovery). In both the soluble and insoluble fractions of the cerebral cortex, we
found no significant differences in any of the Aβ species
measured between the control APP/PS1 and HHcy APP/
PS1 mice (Figure 2D).
We specifically examined the compact amyloid deposits
by Congo red staining. Again, for the 12-month-old

Figure 3 Amyloid is redistributed to the vasculature in the hyperhomocysteinemia APP/PS1 transgenic mice. Congo red staining in the
hippocampi of APP/PS1 mice fed the control diet (A) or the hyperhomocysteinemia (HHcy) diet (B). (A) shows the CA1, CA3 and dentate gyrus
(DG) for orientation. Scale bar = 120 μm for (A) and (B). (C) Quantification of percent area occupied by positive Congo red staining in the
hippocampus and frontal cortex of APP/PS1 transgenic mice on either control (Cont) diet (n = 20, black bars) or the HHcy diet (n = 20, white
bars). Each graph shows total Congo red, parenchymal Congo red and cerebral amyloid angiopathy (CAA) Congo red. **P < 0.01 compared to
APP/PS1 control. Error bars show SEM.
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control APP/PS1 mice, we observed a typical staining pattern in the hippocampus (Figure 3A) and the frontal cortex. What was striking is that we saw showed more Congo
red staining of the cerebrovasculature in the HHcy APP/
PS1 mice (Figure 3B). We quantified this difference using
a previously published method of distinguishing between
cerebral amyloid angiopathy (CAA) and parenchymal
amyloid [21]. We thus found that, whereas total Congo
red levels of the control APP/PS1 mice and HHcy APP/
PS1 mice were not different, HHcy APP/PS1 mice showed
fewer parenchymal amyloid deposits and increased CAA
levels relative to the control APP/PS1 mice. In both the
frontal cortex and hippocampus, we found a 50% to 60%
reduction in parenchymal amyloid and over double the
amount of CAA in the HHcy APP/PS1 mice relative to
the control APP/PS1 mice (P < 0.01) (Figure 3C).
HHcy results in significant induction of microhemorrhage in WT mice [5]. Prussian blue histology was used to
assess microhemorrhage levels. We found that both the
WT and control APP/PS1 mice typically showed few
microhemorrhages, with less than one Prussian blue–positive profile per section. However, HHcy induced significant
microhemorrhages in both the WT and APP/PS1 mice
(P < 0.01) (Figures 4A and 4B). HHcy induced a threefold
increase in microhemorrhages in the WT mice and a fourfold increase in microhemorrhages in the APP/PS1 mice
(Figure 4C). Importantly, the APP/PS1 mice responded to
HHcy with significantly more microhemorrhages than we
saw in the WT mice (P < 0.05) (Figure 4C).
Neuroinflammation is induced by HHcy in WT mice [5].
CD45 immunohistochemistry revealed enhanced microglial activation with HHcy in both the WT and APP/PS1
mice (Figure 5). We found that WT controls had very
little CD45 expression in the brain (Figures 5A and 5E),
but that, with HHcy, WT mice showed microglial activation associated with the cerebrovasculature (Figures 5B
and 5E). Control APP/PS1 mice showed microglial activation associated with the amyloid deposits in the brain
(Figures 5C and 5E), but, following HHcy induction, APP/
PS1 mice showed significantly greater CD45 expression,
particularly in association with the cerebrovasculature
(Figures 5D and 5E).
We further examined the neuroinflammatory response
in the present study by using the macrophage phenotype
categories M1, M2a, M2b and M2c [22,23]. HHcy results
in an M1-type neuroinflammation in WT mice [5]. We
have also previously shown that amyloid-depositing
Tg2576 mice show an M2a phenotype when amyloid has
accumulated [18]. In the present study, we show that
HHcy resulted in increased expression of the M1
markers interleukin 1β (IL-1β), tumor necrosis factor α,
IL-12 and IL-6 in the APP/PS1 mice (Figure 6). Together with this increase in M1 markers, we observed a
concomitant decrease in the M2a markers IL-1- receptor
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Figure 4 Microhemorrhages are increased by
hyperhomocysteinemia in both wild-type and APP/PS1
transgenic mice. (A) and (B) Prussian blue–positive microhemorrhages
in the cerebral cortices of APP/PS1 mice fed the hyperhomocysteinemia
(HHcy) diet. Both images were obtained at 200× original magnification
with a neutral red background stain. Scale bar = 25 μm. (C) Mean
number of microhemorrhages per section for wild-type (WT) and
APP/PS1 transgenic mice fed the control (n = 16 for WT mice and
n = 20 for APP/PS1 mice, black bars) and the HHcy diet (n = 16 for WT
mice and n = 20 for APP/PS1 mice, white bars). **P < 0.01 compared to
the control group for the given genotype. Error bars show SEM.

antagonist, IL-10, Ym1 and Arg1 (Figure 6). The M2b
and M2c phenotypes were largely unaffected in both the
control APP/PS1 and HHcy APP/PS1 mice (Figure 6).
It is well known that matrix metalloproteinase (MMP)
activation, in particular MMP2 and MMP9, is a critical
mediator of hemorrhagic transformation after aneurysm
formation and stroke [24,25]. We have previously shown
that MMPs are activated by anti-Aβ immunotherapy in
studies involving microhemorrhage induction [26], and
we have also shown this activation in WT HHcy mice
[5]. Here we show that gene expression of MMP2 and
MMP9 system components are increased, relative to
WT controls, in both the WT and APP/PS1 mice with
induced HHcy (Figure 7A). In addition, we have found,
by gelatin zymography, increased activity of MMP2 and
MMP9 in both HHcy WT and HHcy APP/PS1 mice
(Figures 7B and 7C). Interestingly, MMP9 activation
was particularly increased in the HHcy APP/PS1 mice
(relative intensity = 8.2), which is significantly greater
than that measured in the HHcy WT mice (relative
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Figure 5 CD45 expression by microglial cells is increased by hyperhomocysteinemia in both wild-type and APP/PS1 mice. CD45
immunohistochemical staining in the frontal cortices of wild-type (WT) mice fed the control diet (A) or the hyperhomocysteinemia (HHcy) diet
(B) and APP/PS1 mice fed the control diet (C) or the HHcy diet (D). Original magnification = 200×. Scale bar = 25 μm. (E) Quantification of percent
area occupied by positive CD45 immunoreactivity in the frontal cortex and hippocampus of WT and APP/PS1 mice on both control (n = 16 for
WT and n = 20 for APP/PS1, black bars) and HHcy diet (n = 16 for WT and n = 20 for APP/PS1, white bars). **P < 0.01 compared to the control group for
a given genotype. Error bars show SEM.

intensity = 6.1) (P < 0.05 for MMP9 activity and gene
expression between HHcy WT and HHcy APP/PS1
mice).

Discussion
Although VaD is the second most common cause of dementia after AD, it remains relatively understudied, with
the challenge being a lack of animal models available to
study the mechanisms by which cerebrovascular disease
leads to dementia. We recently described a model in
which cortical microhemorrhages, neuroinflammation
and cognitive deficits develop when HHcy is induced in
C57BL/6 mice, suggesting that the HHcy model is an

appropriate model for the study of some forms of VaD.
We have been particularly interested in the comorbidity
of VaD and AD, given that it is estimated that around
40% of AD patients also have significant cerebrovascular
disease pathology. To determine the effect of cerebrovascular disease on amyloid pathology, we induced HHcy in
APP/PS1 transgenic mice. We found that the cognitive
deficits are additive when HHcy is induced in APP/PS1
mice. Together with this additive effect, we found a shift
of Aβ from the parenchyma to the vasculature in the
absence of total Aβ changes. In parallel with increased
vascular Aβ, HHcy induced microhemorrhages in both
the WT and APP/PS1 mice, but significantly more
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Figure 6 Hyperhomocysteinemia induces an inflammatory phenotype shift in the APP/PS1 transgenic mice away from M2a and
toward M1. The graph shows fold changes for each gene relative to the wild-type control mice. The dashed line at 1 indicates the normal
wild-type expression of these genes. IL, Interleukin; TNF, Tumor necrosis factor; IL1rn, Interleukin 1 receptor antagonist; Arg1, Arginase type 1; TGF,
Transforming growth factor; FcgR1, Fc gamma receptor 1 *P < 0.05, **P < 0.01 compared to APP/PS1 control (n = 16 for each wild-type group and n =
20 for each APP/PS1 group). Error bars show SEM.

microhemorrhages occurred in the HHcy APP/PS1
mice than in the HHcy WT mice. We saw a strong
neuroinflammatory phenotype switch from an M2a
biased state to an M1 biased state. We also observed an
associated activation of MMP2 and MMP9 systems.
We have previously shown that HHcy can lead to cognitive deficits in WT mice [5]. In addition, in previous
studies of HHcy, researchers have shown behavioral deficits in the Morris water maze test in mice [8] and in the
radial arm maze test in rats [9]. In the present study, we
show that WT mice fed the HHcy-inducing diet developed moderate cognitive deficits similar to those we
have previously described. We have found that these deficits are indistinguishable from those of 12-month-old
APP/PS1 transgenic mice fed a control diet. However,
HHcy APP/PS1 mice showed significantly greater deficits in the radial arm water maze test compared to the
HHcy WT and control APP/PS1 mice. In fact, when we
examined only the mean number of errors per trial for
the final block of testing, we found that the number of
errors made by the HHcy APP/PS1 mice were double
those made by the HHcy WT and the APP/PS1 control
mice, suggesting an additive effect of the amyloid and
cerebrovascular pathology.
The additive effect on cognition of HHcy in APP/PS1
mice is consistent with conclusions derived from a human imaging study published by the Alzheimer’s Disease

Neuroimaging Initiative. These investigators suggested
that cerebrovascular pathology acts independently of AD
pathology, creating an additive effect on overall clinical
dementia [27]. Also, in autopsy studies, researchers have
shown that AD pathology is less severe in patients who
have cerebrovascular disease than in AD patients with
matching cognitive scores who do not have cerebrovascular disease [28]. Further, in a study with clinical outcome
measures of dementia in a population with autopsyconfirmed diagnoses, the researchers found that mixed
pathology (VaD and AD) shows essentially an additive effect on test scores for memory, nonverbal memory and
executive function. Patients with mixed pathology performed more poorly than those with only AD or VaD [29].
Of particular interest in our present study is the apparent redistribution of Aβ deposition to the vasculature.
Previous studies in which researchers induced HHcy in
APP transgenic mice have produced mixed results. Some
investigators have found modest increases in total Aβ
levels [12,13], whereas others have discovered no difference [10,11], with multiple methodological approaches
used across studies. As we show in Figure 2, total Aβ
was unchanged with induction of HHcy. The most
dramatic effect occurred when we separated out the
parenchymal and cerebrovascular amyloid deposition
stained with Congo red. With the use of our previously
published method to separately quantify parenchymal
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Figure 7 Matrix metalloproteinases 2 and 9 are activated by hyperhomocysteinemia in wild-type and APP/PS1 transgenic mice. (A)
Graphed quantitative RT-PCR results for components of the matrix metalloproteinases 2 and 9 (MMP2 and MMP9) systems in both the wild-type
(WT) and APP/PS1 mice. TIMP, Tissue inhibitor of metalloproteinase. **P < 0.01 compared to control (Cont) for the given genotype. (B) Gelatin
zymogram color-inverted to highlight the digested bands in black. As indicated to the right, on the basis of molecular weight, we can determine
that the bands highlighted correspond to pro-MMP9, MMP9, pro-MMP2 and MMP2. H, Hyperhomocysteinemia (HHcy) mice; C, control mice. (C)
Quantification of band density for bands of interest highlighted in (B) for wild-type and control mice. *P < 0.05, **P < 0.01 compared to the control
group for the given genotype (n = 16 for each wild-type group and n = 20 for each APP/PS1 group). Error bars show SEM.

amyloid and CAA [17,21], we found a significant decrease in parenchymal amyloid along with a significant
concomitant increase in CAA.
In previous immunotherapy study [17], we found a
similar redistribution of amyloid, albeit in the presence
of an overall reduction in Aβ, in APP transgenic mice.
In that study, we showed that anti-Aβ immunotherapy
lowers total Aβ but causes a concomitant increase in
CAA deposition. The common link between that study and
our present HHcy study is the modulation of the neuroinflammatory phenotype. Both immunotherapy and HHcy
shift the neuroinflammatory state away from an M2a biased
phenotype to an M1 biased state [18]. The role of the
neuroinflammatory phenotype or, more broadly, microglia

in the regulation of amyloid deposition as CAA or parenchymal plaques is relatively unknown. The results of our
present study further support the concept that modulation
of the neuroinflammatory phenotype is associated with altered distribution of amyloid. Indeed, with immunotherapy, minimizing the interaction between the antibody and
microglia through deglycosylation of the antibody also
minimizes accumulation of amyloid at the vasculature
while preserving the parenchymal amyloid-lowering properties of the antibody [30]. In addition, HHcy is known to
influence vascular function directly [31-33]. It is possible
that the perivascular drainage of Aβ, a major clearance
pathway of Aβ from the brain [34], was affected in our
HHcy mice. Low-density lipoprotein-related protein (LRP)

Sudduth et al. Alzheimer's Research & Therapy 2014, 6:32
http://alzres.com/content/6/3/32

is known to transport Aβ across the endothelium and out
of the brain, and the receptor for advanced glycation end
products (RAGEs) is known to transport Aβ across the
endothelium into the brain. This transport system is also
known to be crucial for the transport of Aβ across the
blood–brain barrier [35,36]. HHcy has been shown to enhance the expression of RAGEs in the vasculature, which
could impact the equilibrium of Aβ between the plasma
and the brain [37]. In future studies, we will examine both
perivascular transport and LRP-RAGE-mediated endothelial transport in the HHcy model.
Consistent with previous findings, in our present
study, HHcy resulted in significant microhemorrhages in
both the WT and APP/PS1 mice, although the APP/PS1
mice showed significantly more microhemorrhages than
the WT mice. There also appears to have been greater
induction of the MMP9 system in the HHcy APP/PS1
mice relative to the HHcy WT mice. Because MMP9 is
heavily implicated in the induction of cerebrovascular
degeneration, we hypothesize that this activation mediates microhemorrhage onset. MMP9 has been shown to
be a critical mediator for hemorrhagic transformation
following a cerebral ischemic event [25], white-matter lesion formation and blood–brain barrier (BBB) breakdown
in VaD [38]. In addition, MMP2 and MMP9 levels have
been shown to be associated with cerebral hemorrhage
resulting from vascular amyloid deposition (that is, CAA)
[39,40]. In our present study, by gelatin zymography, we
investigated not only the expression of components of the
MMP2 and MMP9 systems but also the activity of these
metalloproteinases. Gelatin zymography confirmed that
the activity levels of MMP2 and MMP9 were significantly
increased by HHcy and that this increase was slightly
greater in the APP/PS1 mice than in the WT mice.

Conclusions
We have successfully modeled mixed dementia by combining the HHcy model of VaD with the amyloid-depositing
APP/PS1 transgenic mouse. This novel approach shows
enhanced CAA, altered neuroinflammatory profiles, activation of MMPs and, most importantly, an additive effect on
cognitive outcomes similar to the additive effects seen in
human studies.
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